Anteris Technologies Global Corp.
AVR Healthcare Medical Instruments & Supplies
Anteris Technologies Global Corp.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 million, down 29.2% from fiscal 2024. In the quarter to June 2026, revenue grew 63.3%, EPS grew 48.3%, free cash flow fell 6.84% and total debt rose 8.15%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow AVR
Anteris Technologies Global Corp. (AVR) P/E ratio
Anteris Technologies Global Corp. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 6 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| OSUR OraSure Technologies, Inc. compare | n/m |
| ANGO AngioDynamics, Inc. compare | n/m |
| AVR Anteris Technologies Global Corp. | n/m |
| AZTA Azenta, Inc. compare | n/m |
| SMTI Sanara MedTech Inc. compare | n/m |
| EMBC Embecta Corp. compare | 4.2× |
| STAA STAAR Surgical Company compare | 304× |
| NNNN Anbio Biotechnology compare | — |
| ZJYL Jin Medical International Ltd. compare | — |
| Medical Instruments & Supplies industry median | 33.8× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)